• About us
    • About Lindahl
    • How we work
    • Said about Lindahl
    • Press
    • Find us
    • Privacy
  • Areas
    • Commercial dispute resolution
    • IT/Tech
    • Intellectual property
    • Life Sciences
    • M&A
    • All areas
  • Our people
    • Stockholm
    • Göteborg
    • Malmö
    • Uppsala
    • Helsingborg
    • Örebro
  • Latest news
    • Cases and transactions
    • News
    • Events
    • Knowledge
    • Portraits
  • Offices
    • Stockholm
    • Göteborg
    • Malmö
    • Uppsala
    • Örebro
    • Helsingborg

Lindahl assists when Cyxone signs an asset transfer agreement for a candidate drug in phase 2

  • Home
  • Latest news
  • Cases and transactions
  • 2017
  • Lindahl assists when Cyxone signs an asset transfer agreement for a candidate drug in phase 2

Cyxone AB has signed an agreement regarding the right to acquire the clinical pharmaceutical candidate Rabeximod from OxyPharma AB. Cyxone will call an extraordinary general meeting to seek shareholder approval for a directed new share issue to enable the completion of the acquisition and a phase 2b study within rheumatoid arthritis.

Cyxone is a biopharmaceutical company that develops pharmaceuticals within autoimmune diseases.

Lindahl assisted Cyxone through Anders Burén (life science).

Pages
  • Start
  • About us
  • Areas
  • Our people
  • Latest news
  • Privacy
Our offices
  • Stockholm [email protected] +46 8 527 70 800
  • Göteborg [email protected] +46 31 799 10 00
  • Malmö [email protected] +46 40 664 66 50
  • Uppsala [email protected] +46 18 16 18 50
  • Örebro [email protected] +46 19 20 89 00
  • Helsingborg [email protected] +46 42 17 53 00
Social media
  • Connect with us on social networks: Instagram, Linkedin, Youtube, Facebook,

Disclaimer

The material and information on this site is intended for general informational purposes only and does not constitute legal advice on any specific matter. Please note that all images on Lindahl's website, www.lindahl.se, are subject to intellectual property protection and downloading, publication, copying and/or other use of the images requires the written consent of the rights holder. You'll find Advokatfirman Lindahl KB's general terms and conditions here.

Some cookies are essential, others help us improve your experience by providing insights into how the site is used. For more information, please visit our Cookie Policy.

Essential Cookies

These cookies are necessary for the functionality of the site and cannot be disabled.

Analytics Cookies>

We use Analytics cookies to collect information that gives us insight into how our website is being used. We anonymize IP addresses in Google Analytics. By clicking on Decline we won't save theese cookies.

Decline
We use cookies to get insights on how our site is used and give our visitors the best possible experience